Colorectal LLM Wiki

Browse
Home / Conditions / Colonic and Rectal Neuroendocrine Tumors
Condition created 2026-08-25 · updated 2026-08-25
colorectalneuroendocrineNEToncologytextbookreference

Colonic and Rectal Neuroendocrine Tumors

Neuroendocrine tumors (NETs) of the colon and rectum ("hindgut" NETs), as distinct from midgut (small-bowel) NETs — see Small Bowel Neuroendocrine Tumors (NETs) for general NET biology, carcinoid-syndrome pathophysiology, and the detailed medical-therapy trial synthesis (PROMID, CLARINET, RADIANT-4, NETTER-1), which applies equally here and is not repeated on this page — and from appendiceal NETs, which have their own appendix-specific staging/management algorithm — see Appendiceal Neoplasms. Content below is from a textbook reference chapter (ASCRS Ch34 - GIST, Neuroendocrine Tumors, and Lymphoma), not primary literature.

Epidemiology and terminology

The rectum is the single most common GI-NET site overall (ahead of the small intestine, appendix, and stomach). Historically termed "carcinoid" — a misnomer, as all NENs carry malignant potential; see Small Bowel Neuroendocrine Tumors (NETs) for the full terminology history. Graded WDNET (well-differentiated) vs. PDNET (poorly-differentiated) by mitotic rate and Ki-67 index, consistent with general NET grading conventions.

Clinical presentation and carcinoid syndrome

Most colonic and rectal NETs are asymptomatic and discovered incidentally at colonoscopy performed for another indication (screening, symptoms unrelated to the NET itself). Malignant carcinoid syndrome from a hindgut primary is rare — hindgut NETs characteristically do not produce serotonin (unlike midgut NETs), so carcinoid-syndrome symptoms (flushing, diarrhea, right-sided valvular heart disease) are much less commonly seen with a colonic/rectal primary than a small-bowel one; see Small Bowel Neuroendocrine Tumors (NETs) for the full carcinoid-syndrome mechanism and presentation, which applies when it does occur.

Diagnosis

  • 68Ga-DOTATATE PET/CT: 93% sensitivity / 96% specificity for GI NETs in this source — closely corroborates (not identical to) the 95%/95% figures cited on Small Bowel Neuroendocrine Tumors (NETs) from a smaller study; both point the same direction (DOTATATE-based PET clearly outperforming FDG-PET for well-differentiated NETs, since FDG uptake requires high proliferative activity that most well-differentiated NETs lack).
  • Biochemical workup: chromogranin A (CgA) and 24-hour urinary 5-HIAA, as for other GI NETs (see Small Bowel Neuroendocrine Tumors (NETs) for the full diagnostic-test detail). Table 34.3 in the source lists dietary and medication interferers with 5-HIAA testing — serotonin-rich foods (bananas, avocados, walnuts, tomatoes, pineapple) and drugs affecting serotonin metabolism can cause false elevation, so patients are typically counseled to avoid these before urine collection.

Staging

Colon and rectal NETs are staged with their own site-specific TNM criteria (Tables 34.1–34.2 in the source), distinct from both the general colorectal-adenocarcinoma TNM system (see Colorectal Cancer Staging (TNM)) and the appendiceal-NET-specific TNM system (see Appendiceal Neoplasms).

Treatment

Treatment is driven primarily by tumor size, per Table 34.4 and the Fig. 34.4 algorithm:

  • Small lesions: endoscopic resection (EMR/ESD-type technique — see Endoscopic Polypectomy, EMR & ESD) is favored for very small, low-risk rectal NETs.
  • Intermediate-size lesions: transanal excision / transanal endoscopic surgery (TES) for a middle size tier — full-thickness local excision without the morbidity of radical resection. This mirrors the local-excision approach used for select rectal adenocarcinoma (see Local Excision of Rectal Neoplasms) and rectal GIST (see Gastrointestinal Stromal Tumors (GIST)).
  • Larger or higher-risk lesions: radical (oncologic) resection, analogous to standard rectal cancer surgery (see Total Mesorectal Excision (TME) & Sphincter-Sparing Resection).
  • The 1–2cm zone is a genuine decision point requiring individualized assessment of depth of invasion, grade, and other risk features rather than a fixed size cutoff — broadly analogous to (though a distinct algorithm from) the appendiceal-NET 1–2cm decision zone described on Appendiceal Neoplasms.

For colonic (non-rectal) NETs, surgical management generally follows standard oncologic colon resection principles by location (see Colon Cancer Resection) once a lesion exceeds the size/risk threshold for endoscopic management alone.

Prognosis

Hindgut NETs (rectal/colonic) have a much better prognosis than midgut (small-bowel) NETs — this contrasts with, and adds site-specific nuance to, the prognosis framework on Small Bowel Neuroendocrine Tumors (NETs), which is midgut-focused and does not itself claim this comparison.

Open items / gaps

  • Table 34.4 / Fig. 34.4's full size/grade/depth decision algorithm was summarized narratively above rather than fully transcribed — refer back to ASCRS Ch34 - GIST, Neuroendocrine Tumors, and Lymphoma if exact cutoffs are needed clinically.
  • No primary literature yet in the wiki specific to colonic/rectal NET trials — medical-therapy evidence (SSAs, everolimus, PRRT) is extrapolated from the midgut-NET trial data on Small Bowel Neuroendocrine Tumors (NETs), as this chapter does not present hindgut-specific trial data.
  • The 68Ga-DOTATATE sensitivity/specificity figures here (93%/96%) and on the Small Bowel NETs page (95%/95%) come from different underlying studies cited by different source chapters — not treated as a discrepancy (both support the same clinical conclusion) but noted for precision.